Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Valturna Patent Expiration

Valturna is a drug owned by Novartis Pharmaceuticals Corp. It is protected by 2 US drug patents filed in 2013. Out of these, 1 drug patents are active and 1 has expired. Valturna's patents have been open to challenges since 06 March, 2011. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 03, 2026. Details of Valturna's patents and their expiration are given in the table below.

Patent strength
2
/ 10

Filter patents by

Country : United States (US)
Patent Category : All
Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168616 Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
Jul, 2026

(7 months from now)

Active
US5559111 δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides
Jul, 2018

(7 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Valturna's patents.

Given below is the list of recent legal activities going on the following patents of Valturna.

Activity Date Patent Number
Patent litigations
Expire Patent
Critical
 03 Jun, 2024 US8168616
Maintenance Fee Reminder Mailed
Critical
 18 Dec, 2023 US8168616
Payment of Maintenance Fee, 8th Year, Large Entity 17 Oct, 2019 US8168616
Post Issue Communication - Certificate of Correction 23 Jul, 2013 US8168616
Patent Issue Date Used in PTA Calculation
Critical
 01 May, 2012 US8168616
Recordation of Patent Grant Mailed
Critical
 01 May, 2012 US8168616
Email Notification
Critical
 12 Apr, 2012 US8168616
Issue Notification Mailed
Critical
 11 Apr, 2012 US8168616
Dispatch to FDC 04 Apr, 2012 US8168616
Application Is Considered Ready for Issue
Critical
 29 Mar, 2012 US8168616


FDA has granted several exclusivities to Valturna. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Valturna, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Valturna.

Exclusivity Information

Valturna holds 2 exclusivities. All of its exclusivities have expired in 2012. Details of Valturna's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 05, 2012
New Combination(NC) Sep 16, 2012

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Valturna is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Valturna's family patents as well as insights into ongoing legal events on those patents.

Valturna's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Valturna's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 03, 2026 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Valturna Generics:

There are no approved generic versions for Valturna as of now.

Alternative Brands for Valturna

Valturna which is used for managing high blood pressure., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Abbott
Hytrin Used for treating hypertension and symptomatic benign prostatic hyperplasia.
Abbvie
Teveten Used for managing high blood pressure.
Teveten Hct Used for managing high blood pressure.
Adhera
Prestalia Used for treating high blood pressure.
Allergan
Bystolic Used for treating high blood pressure.
Ani Pharms
Atacand Hct Used for treating high blood pressure.
Azurity
Edarbi Used for lowering blood pressure.
Epaned Used for managing heart failure and hypertension.
Qbrelis Used for treating acute myocardial infarction, hypertension, and heart failure.
Edarbyclor Used for managing high blood pressure.
Boehringer Ingelheim
Twynsta Used for managing high blood pressure.
Micardis Used for the treatment of cardiovascular conditions such as myocardial infarction, hypertension, and stroke.
Micardis Hct Used for lowering high blood pressure.
Cosette
Azor Used for managing high blood pressure.
Benicar Used for lowering high blood pressure.
Tribenzor Used for lowering high blood pressure.
Benicar Hct Used for managing high blood pressure.
Noden Pharma
Tekturna Used for treating high blood pressure.
Tekturna Hct Used for lowering high blood pressure.
Novartis
Diovan Used for managing hypertension and reducing cardiovascular mortality in stable patients with left ventricular failure or dysfunction post-myocardial infarction.
Exforge Used for treating high blood pressure.
Tekamlo Used for treating high blood pressure.
Amturnide Used for lowering high blood pressure (hypertension).
Diovan Hct Used for treating high blood pressure.
Exforge Hct Used for treating high blood pressure.
Upjohn
Inspra Used for treating hypertension, heart failure, and conditions related to hyperaldosteronism, often in combination with an ACE inhibitor.
Waylis Therap
Coreg Cr Used for managing congestive heart failure and hypertension to reduce mortality.





About Valturna

Valturna is a drug owned by Novartis Pharmaceuticals Corp. It is used for managing high blood pressure. Valturna uses Aliskiren Hemifumarate; Valsartan as an active ingredient. Valturna was launched by Novartis in 2009.

Approval Date:

Valturna was approved by FDA for market use on 16 September, 2009.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Valturna is 16 September, 2009, its NCE-1 date is estimated to be 06 March, 2011.

Active Ingredient:

Valturna uses Aliskiren Hemifumarate; Valsartan as the active ingredient. Check out other Drugs and Companies using Aliskiren Hemifumarate; Valsartan ingredient

Treatment:

Valturna is used for managing high blood pressure.

Dosage:

Valturna is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 300MG BASE;320MG TABLET Discontinued ORAL
EQ 150MG BASE;160MG TABLET Discontinued ORAL